At a glance
ClinicalIndex Comparison Record- ✓Bone mineral density T-score less than -1.0
- ✓One or more vertebral fractures
- ✓Serum creatinine less than 1.3 mg/dL
- ✓Serum phosphorus less than 3.6 mg/dL
- ✕Paget's disease or history of osteosarcoma
- ✕Systemic corticosteroid therapy
- ✕Hyperparathyroidism
- ✕Recent history of kidney stone
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bone Sparing by Calcium Salts With and Without Extra Phosphorus
In Brief
A Phase 2 clinical trial evaluating Calcium carbonate and Calcium Phosphate for Osteoporosis and Osteopenia. Completed, enrolled 241 participants across 1 site.
Detailed Summary
Osteoporosis causes bones to weaken and break more easily. Calcium and phosphorus are two minerals that are essential for normal bone formation. Unfortunately, calcium salts commonly prescribed in anti-osteoporosis treatment bind phosphorus from food and restrict phosphorus available for bone building. Teriparatide is a drug that reduces the risk of fractures by increasing bone thickness and strength. Vitamin D is also necessary for strong bones and teeth. The purpose of this study is to evaluate the bone-building effectiveness of two calcium supplements, one with a source of phosphorus and one without, in combination with teriparatide and vitamin D in women with osteoporosis.
Study Details
Timeline
Interventions
Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.